NDLI: Immunotherapy for prostate cancer: recent developments and future challenges

Content Provider	Springer Nature Link
Author	Schweizer, Michael T. Drake, Charles G.
Copyright Year	2014
Abstract	Since the approval of sipuleucel-T for men with metastatic castrate resistant prostate cancer in 2010, great strides in the development of anti-cancer immunotherapies have been made. Current drug development in this area has focused primarily on antigen-specific (i.e. cancer vaccines and antibody based therapies) or checkpoint inhibitor therapies, with the checkpoint inhibitors perhaps gaining the most attention as of late. Indeed, drugs blocking the inhibitory signal generated by the engagement of cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) found on T-cells has emerged as potent means to combat the immunosuppressive milieu. The anti-CTLA-4 monoclonal antibody ipilimumab has already been approved in advanced melanoma and two phase III trials evaluating ipilimumab in men with metastatic castrate-resistant prostate cancer are underway. A phase III trial evaluating ProstVac-VF, a poxvirus-based therapeutic prostate cancer vaccine, is also underway. While there has been reason for encouragement over the past few years, many questions regarding the use of immunotherapies remain. Namely, it is unclear what stage of disease is most likely to benefit from these approaches, how best to incorporate said treatments with each other and into our current treatment regimens and which therapy is most appropriate for which disease. Herein we review some of the recent advances in immunotherapy as related to the treatment of prostate cancer and outline some of the challenges that lie ahead.
Starting Page	641
Ending Page	655
Page Count	15
File Format	PDF
ISSN	01677659
Journal	Cancer and Metastasis Reviews
Volume Number	33
Issue Number	2-3
e-ISSN	15737233
Language	English
Publisher	Springer US
Publisher Date	2014-01-30
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Immunotherapy Immune checkpoints Prostate cancer T-cell Vaccine Cancer Research Oncology Biomedicine general
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Adoptive immunotherapy of metastatic breast cancer: present and future

Immunotherapy for Prostate Cancer – Recent Developments and Future Challenges

Current status of immunological approaches for the treatment of prostate cancer

Current status of immunological therapies for prostate cancer

Immunotherapy for prostate cancer: recent developments and future challenges.

Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.

Regulatory T cells and potential inmmunotherapeutic targets in lung cancer

Recent progress on nutraceutical research in prostate cancer

Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives

Immunotherapy for prostate cancer: recent developments and future challenges

Similar Documents

Adoptive immunotherapy of metastatic breast cancer: present and future

Immunotherapy for Prostate Cancer – Recent Developments and Future Challenges

Current status of immunological approaches for the treatment of prostate cancer

Current status of immunological therapies for prostate cancer

Immunotherapy for prostate cancer: recent developments and future challenges.

Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.

Regulatory T cells and potential inmmunotherapeutic targets in lung cancer

Recent progress on nutraceutical research in prostate cancer

Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives

Immunotherapy for prostate cancer: recent developments and future challenges